Second, although this framework focused on granulosa cell tumors treated with a TRAIL-producing oncolytic virus and PAC-1, extending the methodology to other tumor types and therapeutic combinations could broaden its clinical applicability. This evidence concerns the gene TNFSF10 and granulosa cell tumor.